Opus Genetics, Inc. announced the dosing of the first pediatric patient in its Phase 1/2 trial for OPGx-LCA5, a gene therapy targeting Leber congenital amaurosis (LCA). Initial results from this ...

The ACTIVATE-Kids and ACTIVATE-KidsT Phase 3 studies mark Agios’ first pediatric clinical program for a rare hemolytic anemia, providing valuable insights that will help shape the company’s ...

About the CIDS Phase III The CIDS Phase III was a multicenter, multinational, randomized, controlled, open label study, conducted in pediatric patients with deep partial thickness (DPT ...

Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.

Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with Tourette syndrome.

Engineers from the UK have made significant progress in using the stratosphere for surveillance and communication purposes with the completion of a series of trials with the PHASA-35, an uncrewed ...

The Pedi tribe practises many cultural customs and also take part in many cultural practices, the main one is called “Go ...

MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable tissue in patients with deep partial- and full-thickness thermal burns. It is ...